{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:47:35Z","timestamp":1760647655139,"version":"3.41.2"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007388","name":"Compagnia di San Paolo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) have been improving the prognosis of patients with chronic myeloid leukemia (CML), but there are still large differences in survival among European countries. This raises questions on the added value of results from population-based studies, which use real-world data, compared to results of randomized controlled trials (RCTs) involving patients with CML. There are also questions about the extent of the findings on RCTs effectiveness for patients in the general population. We compare survival data extracted from our previous systematic review and meta-analysis of CML RCTs with the latest updated population-based survival data of EUROCARE-6, the widest collaborative study on cancer survival in Europe. The EUROCARE-6 CML survival estimated in patients (15\u201364 years) diagnosed in 2000\u20132006 vs. 2007\u20132013 revealed that the prognostic improvement highlighted by RCTs was confirmed in real-world settings, too. The study shows, evaluating for the first time all European regions, that the optimal outcome figures obtained in controlled settings for CML are also achievable (and indeed achieved) in real-world settings with prompt introduction of TKIs in daily clinical practice. However, some differences still persist, particularly in Eastern European countries, where overall survival values are lower than elsewhere, probably due to a delayed introduction of TKIs. Our results suggest an insufficient adoption of adequate protocols in daily clinical practice in those countries where CML survival values remain lower in real life than the values obtained in RCTs. New high-resolution population-based studies may help to identify failures in the clinical pathways followed there.<\/jats:p>","DOI":"10.3389\/fonc.2022.892684","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T16:17:39Z","timestamp":1658247459000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Claudia","family":"Vener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Minicozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Marcos-Gragera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne A.","family":"Poirel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Maynadi\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Troussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Pravettoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Sant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the EUROCARE-6 Working Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of Hematologic Malignancies in Europe by Morphologic Subtype: Results of the HAEMACARE Project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"JCO"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS Population-Based Registry: Incidence and Clinical Characteristics of 2904 CML Patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008","author":"Swerdlow","key":"B4"},{"key":"B5","article-title":"An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561","article-title":"Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"B8","article-title":"Inhibition of the Abl Protein-Tyrosine Kinase In Vitro and In Vivo by a 2-Phenylaminopyrimidine Derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00025-9","article-title":"Perspectives on the Development of a Molecularly Targeted Agent","volume":"1","author":"Druker","year":"2002","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for Haematological Malignancies in Europe Between 1997 and 2008 by Region and Age: Results of EUROCARE-5, a Population-Based Study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.04.003","article-title":"A Population Study Showing That the Advent of Second Generation Tyrosine Kinase Inhibitors has Improved Progression-Free Survival in Chronic Myeloid Leukaemia","volume":"37","author":"Francis","year":"2013","journal-title":"Leuk Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.08.003","article-title":"Survival Variations by Country and Age for Lymphoid and Myeloid Malignancies in Europe 2000-2007: Results of EUROCARE-5 Population-Based Study","volume":"51","author":"De Angelis","year":"2015","journal-title":"EJC"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.03.018","article-title":"Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia","volume":"123","author":"Wiggins","year":"2010","journal-title":"Am J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3109\/10428194.2014.947610","article-title":"Is Survival in Myeloid Malignancies Really Improving? A Retrospective 15 Year Population-Based Study","volume":"56","author":"Osca-Gelis","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B15","unstructured":"MarmotM\n          Fair Society, Healthy Lives. The Marmot Review. Strategic Review of Health Inequalities in England Post-2010"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.025","article-title":"Age and Case Mix-Standardised Survival for All Cancer Patients in Europe 1999-2007: Results of EUROCARE-5, a Population-Based Study","volume":"51","author":"Baili","year":"2015","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1312","article-title":"Deconstructing Clinical Trials-Help From Oncology Value Frameworks","volume":"3","author":"Del Paggio","year":"2017","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4915","article-title":"Utility of Cancer Value Frameworks for Patients, Payers, and Physicians","volume":"315","author":"Chandra","year":"2016","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4345","article-title":"Medians and Milestones in Describing the Path to Cancer Cures: Telling \u201cTails\u201d","volume":"2","author":"Hellmann","year":"2016","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2016.03.066","article-title":"Bias in Reporting of Randomised Clinical Trials in Oncology","volume":"61","author":"Vera-Badillo","year":"2016","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30572-1","article-title":"Relevance of Randomised Controlled Trials in Oncology","volume":"17","author":"Tannock","year":"2016","journal-title":"Lancet Oncol"},{"key":"B22","unstructured":"EUROCARE Survival of Cancer Patients in Europe"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/blood.V116.21.206.206","article-title":"Dasatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the DASISION Trial: 18-Month Follow-Up","volume":"116","author":"Shah","year":"2010","journal-title":"Blood (ASH Annu Meeting Abstracts)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6510","DOI":"10.1200\/jco.2011.29.15_suppl.6510","article-title":"Dasatinib or Imatinib (IM) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Two-Year Follow-Up From DASISION","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J Clin Oncol (ASCO Annu Meeting Abstracts)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1182\/blood.V118.21.2767.2767","article-title":"Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% at 3 Months Are Associated With Improved Responses in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial. [Abstract]","volume":"118","author":"Hochhaus","year":"2011","journal-title":"Blood (ASH Annu Meeting Abstracts)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6504","DOI":"10.1200\/jco.2012.30.15_suppl.6504","article-title":"Dasatinib Versus Imatinib (IM) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): DASISION 3-Year Follow-Up","volume":"30","author":"Hochhaus","year":"2012","journal-title":"J Clin Oncol (ASCO Annu Meeting Abstracts)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: 2-Year Follow-Up From a Randomized Phase 3 Trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early Response With Dasatinib or Imatinib in Chronic Myeloid Leukemia: 3-Year Follow-Up From a Randomized Phase 3 Trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1182\/blood.V122.21.653.653","article-title":"Four-Year (Yr) Follow-Up of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Receiving Dasatinib or Imatinib: Efficacy Based on Early Response","volume":"122","author":"Cortes","year":"2013","journal-title":"Blood (ASH Annu Meeting Abstracts)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056)","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood (ASH Annu Meeting Abstracts)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410688","article-title":"A Randomized Trial of Dasatinib 100 Mg Versus Imatinib 400 Mg in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","volume":"120","author":"Radich","year":"2012","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.19","article-title":"Impact of Malignant Stem Cell Burden on Therapy Outcome in Newly Diagnosed Chronic Myeloid Leukemia Patients","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1182\/blood.V122.21.4032.4032","article-title":"Dasatinib Treatment Induces Fast and Deep Responses in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase: Clinical Results From a Randomised Phase-2 Study (Nordcml006)","volume":"122","author":"Hjorth-Hansen","year":"2013","journal-title":"Blood (ASH Annu Meeting Abstracts)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12423","article-title":"Dasatinib Induces Fast and Deep Responses in Newly Diagnosed Chronic Myeloid Leukaemia Patients in Chronic Phase: Clinical Results From a Randomised Phase-2 Study (Nordcml006)","volume":"94","author":"Hjorth-Hansen","year":"2015","journal-title":"Eur J Haematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1200\/jco.2010.28.15_suppl.6501","article-title":"Comparison of Nilotinib and Imatinib in Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year","volume":"28","author":"Larson","year":"2010","journal-title":"J Clin Oncol (ASCO Annu Meeting Abstracts)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"B39","article-title":"ENESTnd update: Continued Superiority of Nilotinib Versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib Versus Imatinib for the Treatment of Patients With Newly Diagnosed Chronic Phase, Philadelphia Chromosome-Positive, Chronic Myeloid Leukaemia: 24-Month Minimum Follow-Up of the Phase 3 Randomised ENESTnd Trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1182\/blood.V120.21.1676.1676","article-title":"Enestnd 4-Year (Y) Update: Continued Superiority of Nilotinib vs Imatinib in Patients (Pts) With Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). [Abstract]","volume":"120","author":"Kantarjian","year":"2012","journal-title":"Blood (ASH Annu Meeting Abstracts)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 3-Year Follow-Up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-423418","article-title":"Nilotinib Is Associated With a Reduced Incidence of BCR-ABL Mutations vs Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase","volume":"121","author":"Hochhaus","year":"2013","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early Molecular Response Predicts Outcomes in Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Frontline Nilotinib or Imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5","article-title":"Long-Term Benefits and Risks of Frontline Nilotinib vs Imatinib for Chronic Myeloid Leukemia in Chronic Phase: 5-Year Update of the Randomized ENESTnd Trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1182\/blood.V126.23.2781.2781","article-title":"Impact of Treatment With Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-Cp)","volume":"126","author":"Hochhaus","year":"2015","journal-title":"Blood (ASH Annu Meeting Abstracts)"},{"key":"B47","first-page":"P228","article-title":"Efficacy and Safety of Nilotinib vs Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: 6-Year Follow-Up of ENESTND","volume":"100480","author":"Hughes","year":"2015","journal-title":"Haematologica (EHA-European Hematol Assoc Library)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1200\/jco.2011.29.15_suppl.6509","article-title":"Bosutinib (BOS) Versus Imatinib (IM) in Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP CML) in the BELA Trial: 18-Month Follow-Up","volume":"29","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Clin Oncol (ASCO Annu Meeting Abstracts)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia: Results From the 24-Month Follow-Up of the BELA Trial","volume":"168","author":"Br\u00fcmmendorf","year":"2015","journal-title":"Br J Haematol"},{"key":"B51","first-page":"0587","article-title":"Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia: 30-Month Update of the BELA Trial","volume":"97","author":"Br\u00fcmmendorf","year":"2012","journal-title":"Haematologica (EHA-European Hematol Assoc Meeting Abstracts)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23788","article-title":"Safety of Bosutinib Versus Imatinib in the Phase 3 BELA Trial in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24360","article-title":"Long-Term Evaluation of Cardiac and Vascular Toxicity in Patients With Philadelphia Chromosome-Positive Leukemias Treated With Bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood.V130.Suppl_1.896.896","article-title":"Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukaemia (CML) in the BFORE Trial: 18-Month Follow-Up","volume":"130","author":"Gambacorti-Passerini","year":"2017","journal-title":"Blood (ASH Annu Meeting Abstracts)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-137393","article-title":"Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results From the Bfore Trial","volume":"136","author":"Br\u00fcmmendorf","year":"2020","journal-title":"Blood (ASH Annu Meeting Abstracts)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukaemia: An International, Randomised, Open-Label, Phase 3 Trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-Line Imatinib Versus 2nd and 3rd Generation TKIs for Chronic Phase CML: Systematic Review and Meta-Analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv"},{"key":"B59","unstructured":"VenerC\n            FerreroA\n            BanziR\n            PistottiV\n            Del GiovaneC\n            SantM"},{"volume-title":"International Classification of Disease for Oncology (ICD-O), 3rd Edn","year":"2000","author":"Fritz","key":"B60"},{"key":"B61","first-page":"i","article-title":"Manual for Coding and Reporting Haematological Malignancies","volume":"96","year":"2010","journal-title":"Tumori"},{"key":"B62","article-title":"Giusti F and the Cancer Data Quality Checks Working Group. A Proposal on Cancer Data Quality Checks","volume-title":"One Common Procedure for European Cancer Registries - Version 1.1","author":"Martos","year":"2018"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9697","article-title":"Clinical Relevance of Conditional Survival of Cancer Patients in Europe: Age-Specific Analyses of 13 Cancers","volume":"28","author":"Janssen-Heijnen","year":"2010","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.08.001","article-title":"The EUROCARE-5 Study on Cancer Survival in Europe 1999-2007: Database, Quality Checks and Statistical Analysis Methods","volume":"51","author":"Rossi","year":"2015","journal-title":"Eur J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.10.013","article-title":"Period Analysis for \u2018Up-Todate\u2019 Cancer Survival Data: Theory, Empirical Evaluation, Computational Realisation and Applications","volume":"40","author":"Brenner","year":"2004","journal-title":"Eur J Cancer"},{"key":"B66","article-title":"The Relative Survival: A Statistical Methodology","volume":"6","author":"Ederer","year":"1961","journal-title":"Natl Cancer Inst Monogr"},{"volume-title":"The Natural Duration of Cancer (Report on Public Health and Medical Subjects No. 33)","year":"1926","author":"Greenwood","key":"B67"},{"key":"B68","article-title":"Cancer Registration: Principles and Methods. Analysis of Survival","volume":"95","author":"Parkin","year":"1991","journal-title":"IARC Sci Publ"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting Summary Statistics to Perform Meta-Analyses of the Published Literature for Survival Endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine Kinase Inhibitor Usage, Treatment Outcome, and Prognostic Scores in CML: Report From the Population-Based Swedish CML Registry","volume":"122","author":"H\u00f6glund","year":"2013","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12743","article-title":"Population-Based Assessment of Chronic Myeloid Leukemia in Sweden: Striking Increase in Survival and Prevalence","volume":"97","author":"Gunnarsson","year":"2016","journal-title":"Eur J Haematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004266","article-title":"Determinants of Survival in Patients With Chronic Myeloid Leukaemia Treated in the New Era of Oral Therapy: Findings From a UK Population-Based Patient Cohort","volume":"4","author":"Smith","year":"2014","journal-title":"BMJ Open"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-010-1450-x","article-title":"First Annual Report of the Austrian CML Registry","volume":"122","author":"Schmidt","year":"2010","journal-title":"Wien Klin Wochenschr"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24591","article-title":"A Population-Based Study of Chronic Myeloid Leukemia Patients Treated With Imatinib in First Line","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am J Hematol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"6269","DOI":"10.3390\/cancers13246269","article-title":"Potential to Improve Therapy of Chronic Myeloid Leukemia (CML), Especially for Patients With Older Age: Incidence, Mortality, and Survival Rates of Patients With CML in Switzerland From 1995 to 2017","volume":"13","author":"Daskalakis","year":"2021","journal-title":"Cancers"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01637.x","article-title":"Treatment of Consecutive Patients With Chronic Myeloid Leukaemia in the Cooperating Centres From the Czech Republic and the Whole of Slovakia After 2000- a Report From the Population-Based CAMELIA Registry","volume":"87","author":"Faber","year":"2011","journal-title":"Eur J Haematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12695","article-title":"Chronic Myeloid Leukemia in the Netherlands: A Population-Based Study on Incidence, Treatment, and Survival in 3585 Patients From 1989 to 2012","volume":"97","author":"Thielen","year":"2016","journal-title":"Eur J Haematol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.exphem.2018.05.003","article-title":"Long-Term Follow-Up of De Novo Chronic Phase Chronic Myelogenous Leukemia Patients on Front-Line Imatinib","volume":"64","author":"Nicolini","year":"2018","journal-title":"Exp Hematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.974046","article-title":"Incidence of Chronic Myeloid Leukemia and Patient Survival: Results of Five French Population-Based Cancer Registries 1980-2009","volume":"56","author":"Penot","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B81","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and Outcome of 2904 CML Patients From the EUTOS Population-Based Registry","volume":"31","author":"Hoffmann","year":"2017","journal-title":"Leukemia"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in Chronic Myeloid Leukemia Incidence and Survival in the United States From 1975 to 2009","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28106","article-title":"Trends in All-Cause Mortality Among Patients With Chronic Myeloid Leukemia: A Surveillance, Epidemiology, and End Results Database Analysis","volume":"119","author":"Brunner","year":"2013","journal-title":"Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14061","article-title":"Incidence and Patient Survival of Myeloproliferative Neoplasms and Myelodysplastic\/Myeloproliferative Neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31822a7047","article-title":"Cancer Trials Versus the Real World in the United States","volume":"254","author":"Al-Refaie","year":"2011","journal-title":"Ann Surg"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"B87","unstructured":"Haematological Malignancies in Belgium 2004-2018Belgian Cancer Registry - PublicationsBelgian Cancer Registry, Brussels2021"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.892684\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T16:17:54Z","timestamp":1658247474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.892684\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":87,"alternative-id":["10.3389\/fonc.2022.892684"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.892684","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"article-number":"892684"}}